NRG GY012: A randomized phase II study comparing single-agent olaparib, single agent cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent or metastatic endometrial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results